A recombinant humanized monoclonal antibody (tocilizumab) of the IgG subclass directed against the soluble and membrane bound IL-6, approved for the use of rheumatic conditions, has been shown to be successful in pilot studies and case reports in IBD [127,128]. Here, IL6 is linked to inflammatory bowel disease.